Analysis of intercellular calcium signaling using microfluidic adjustable laminar flow for localized chemical stimulation.

Jian Sun,Ying Zheng,Xiaojun Feng,Wei Du,Bifeng Liu

DOI: https://doi.org/10.1016/j.aca.2012.01.053

IF: 6.911

2012-04-06

Analytica Chimica Acta

Abstract:

What problem does this paper attempt to address?

Comparison of Artificial Neural Network and Regression Models in the Prediction of Urban Stormwater Quality

Daniel May,M. Sivakumar

DOI: https://doi.org/10.2175/106143007X184591

2008-01-01

Water Environment Research

Abstract:Urban stormwater quality is influenced by many interrelated processes. However, the site‐specific nature of these complex processes makes stormwater quality difficult to predict using physically based process models. This has resulted in the need for more empirical techniques. In this study, artificial neural networks (ANN) were used to model urban stormwater quality. A total of 5 different constituents were analyzed—chemical oxygen demand, lead, suspended solids, total Kjeldahl nitrogen, and total phosphorus. Input variables were selected using stepwise linear regression models, calibrated on logarithmically transformed data. Artificial neural networks models were then developed and compared with the regression models. The results from the analyses indicate that multiple linear regression models were more applicable for predicting urban stormwater quality than ANN models.
Predictors of Venous Thromboembolism after Lung Cancer Resection

Andrea L. Axtell,Henning A. Gaissert,Xiaodong Bao,Hugh G. Auchincloss,Elisa Walsh,David C. Chang,Yolanda L. Colson,Michael Lanuti

DOI: https://doi.org/10.1016/j.athoracsur.2024.01.005

IF: 5.113

2024-01-31

The Annals of Thoracic Surgery

Abstract:BACKGROUND Venous thromboembolism (VTE) is a major cause of morbidity and mortality in patients undergoing oncologic surgery. We sought to identify risk factors for postoperative VTE to define high-risk groups which may benefit from enhanced prophylactic measures. METHODS A retrospective cohort analysis using the STS General Thoracic Surgery Database was conducted on patients who underwent lung cancer resection between 2009-2021. Baseline characteristics and postoperative outcomes were compared between patients who did and did not develop a postoperative pulmonary embolism (PE) or deep venous thrombosis. Multivariable regression models identified risk factors associated with VTE. RESULTS Of 57,531 patients who underwent lung cancer resection, 758 (1.3%) developed a postoperative PE. Patients with PE were more likely to be black (12% vs 7%, p<0.001), have interstitial fibrosis (3% vs 2%, p=0.016), and prior VTE (12% vs 6%, p<0.001.) Patients with locally-advanced disease who underwent bilobectomy (6% vs 4%, p<0.001) or pneumonectomy (8% vs 5%, p<0.001) were more likely to develop postoperative PE. Patients with postoperative PE had increased 30-day mortality (14% vs 3%, p<0.001), reintubation (25% vs 8%, p<0.001), and readmission (49% vs 15%, p<0.001.) On multivariable analysis, black race (OR 1.74 [1.39-2.16], p<0.001), interstitial fibrosis (OR 1.77 [1.15-2.72], p=0.009), extent of resection, and increased operative duration were independently predictive of postoperative PE. A minimally invasive approach compared to thoracotomy was protective. CONCLUSIONS Because non-modifiable risk factors (black race, interstitial fibrosis, and advanced-stage disease) predominate in postoperative PE and VTE-associated mortality is increased, enhanced perioperative prophylactic measures should be considered in high-risk cohorts.

surgery,cardiac & cardiovascular systems,respiratory system
Incidence and timing of venous thromboembolism after surgery for gynecological cancer

Abraham Peedicayil,Amy Weaver,Xujian Li,Erin Carey,William Cliby,Andrea Mariani

DOI: https://doi.org/10.1016/j.ygyno.2010.11.038

IF: 5.304

2011-04-01

Gynecologic Oncology

Abstract:OBJECTIVE: This study aims to determine the incidence, timing, and risk factors of clinical venous thromboembolism.METHODS: A cohort of patients who had major gynecologic cancer surgery between 1998 and 2008 was identified. Secondarily, a nested case-control design wherein patients who had clinical VTE within 90 days after surgery were considered cases. Controls were matched on age, race, surgery date, and cancer site. Risk factors were evaluated for VTE within 90 days, and late VTE between 8 and 90 days.RESULTS: We identified 4158 women, 18 years or older, without a history of recent thrombosis. We observed 126 cases of clinical VTE within 90 days of surgery (incidence 4%) of which 96 (76%) occurred after post-operative day 7. In a multivariable model including age, ASA, BMI, race, and site of cancer, only ovarian cancer was a significant predictor for VTE within 90 days (HR 2.8; 95% CI 1.6, 5.0). In the nested case-control study, we identified hospital stay ≥ 5 days (OR 2.8; 95% CI 1.5, 5.1) and prior VTE (OR 2.6; 95% CI 1.1, 6.1) as significant risk factors for VTE within 90 days. Only hospital stay ≥ 5 days (OR 2.5; 95% CI 1.3, 4.7) was significantly associated with late VTE between 8 and 90 days.CONCLUSION: In gynecologic cancer patients, over 75% of VTE are detected more than 7 days after surgery. Patients with ovarian cancer, prolonged hospitalization, or a history of VTE are at highest risk of developing clinical VTE. Such patients would be optimal candidates for clinical trials evaluating extended VTE prophylaxis.

oncology,obstetrics & gynecology
Venous Thromboembolism Chemoprophylaxis Adherence Rates After Major Cancer Surgery

Charles D Logan,Matthew T Hudnall,Cary Jo R Schlick,Dustin D French,Brian Bartle,Dominic Vitello,Hiten D Patel,Lauren M Woldanski,Daniel E Abbott,Ryan P Merkow,David D Odell,David J Bentrem

DOI: https://doi.org/10.1001/jamanetworkopen.2023.35311

2023-09-05

Abstract:Importance: Venous thromboembolism (VTE) represents a major source of preventable morbidity and mortality and is a leading cause of death in the US after cancer surgery. Previous research demonstrated variability in VTE chemoprophylaxis prescribing, although it is unknown how these rates compare with performance in the Veterans Health Administration (VHA). Objective: To determine VTE rates after cancer surgery, as well as rates of inpatient and outpatient (posthospital discharge) chemoprophylaxis adherence within the VHA. Design, setting, and participants: This retrospective cohort study within 101 hospitals of the VHA health system included patients aged 41 years or older without preexisting bleeding disorders or anticoagulation usage who underwent surgical treatment for cancer with general surgery, thoracic surgery, or urology between January 1, 2015, and December 31, 2022. The VHA Corporate Data Warehouse, Pharmacy Benefits Management database, and the Veterans Affairs Surgical Quality Improvement Program database were used to identify eligible patients. Data analysis was conducted between January 2022 and July 2023. Exposures: Inpatient surgery for cancer with general surgery, thoracic surgery, or urology. Main outcomes and measures: Rates of postoperative VTE events within 30 days of surgery and VTE chemoprophylaxis adherence were determined. Multivariable Poisson regression was used to determine incidence-rate ratios of inpatient and postdischarge chemoprophylaxis adherence by surgical specialty. Results: Overall, 30 039 veterans (median [IQR] age, 67 [62-71] years; 29 386 men [97.8%]; 7771 African American or Black patients [25.9%]) who underwent surgery for cancer and were at highest risk for VTE were included. The overall postoperative VTE rate was 1.3% (385 patients) with 199 patients (0.7%) receiving a diagnosis during inpatient hospitalization and 186 patients (0.6%) receiving a diagnosis postdischarge. Inpatient chemoprophylaxis was ordered for 24 139 patients (80.4%). Inpatient chemoprophylaxis ordering rates were highest for patients who underwent procedures with general surgery (10 102 of 10 301 patients [98.1%]) and lowest for patients who underwent procedures with urology (11 471 of 17 089 patients [67.1%]). Overall, 3142 patients (10.5%) received postdischarge chemoprophylaxis, with notable variation by specialty. Conclusions and relevance: These findings indicate the overall VTE rate after cancer surgery within the VHA is low, VHA inpatient chemoprophylaxis rates are high, and postdischarge VTE chemoprophylaxis prescribing is similar to that of non-VHA health systems. Specialty and procedure variation exists for chemoprophylaxis and may be justified given the low risks of overall and postdischarge VTE.
Postoperative Venous Thromboembolism in Colon and Rectal Cancer: Do Tumor Location and Operation Matter?

Nicholas P McKenna,Katherine A Bews,Kevin T Behm,Elizabeth B Habermann,Robert R Cima

DOI: https://doi.org/10.1097/xcs.0000000000000537

2023-03-17

Journal of the American College of Surgeons

Abstract:BACKGROUND: Existing venous thromboembolism (VTE) risk scores help identify patients at increased risk of postoperative VTE who warrant extended prophylaxis in the first 30 days. However, these methods do not address factors unique to colorectal surgery, wherein the tumor location and operation performed vary widely. VTE risk may extend past 30 days. Therefore, we aimed to determine the roles of tumor location and operation in VTE development and evaluate VTE incidence through 90 days postoperatively. STUDY DESIGN: Adult patients undergoing surgery for colorectal cancer between January 1, 2005, and December 31, 2021, at a single institution were identified. Patients were then stratified by cancer location and by operative extent. VTEs were identified using diagnosis codes in the electronic medical record and consisted of extremity deep venous thromboses, portomesenteric venous thromboses, and pulmonary emboli. RESULTS: A total of 6,844 operations were identified (72% segmental colectomy, 22% proctectomy, 6% total (procto)colectomy), and tumor location was most commonly in the ascending colon (32%), followed by the rectum (31%), with other locations less common (sigmoid 16%, rectosigmoid junction 9%, transverse colon 7%, descending colon 5%). The cumulative incidence of any VTE was 3.1% at 90 days with a relatively steady increase across the entire 90-day interval. Extremity deep venous thromboses were the most common VTE type, accounting for 37% of events, and pulmonary emboli and portomesenteric venous thromboses made up 33% and 30% of events, respectively. More distal tumor locations and more anatomically extensive operations had higher VTE rates. CONCLUSIONS: When considering extended VTE prophylaxis after colorectal surgery, clinicians should account for the operation performed and the location of the tumor. Further study is necessary to determine the optimal length of VTE prophylaxis in high-risk individuals.

surgery
Incidence and Predictors of Venous Thromboembolism after Surgery for Gynecologic Cancer

Xiao-Juan Wang,Ke-Qin Hua

DOI: https://doi.org/10.31083/j.ejgo.2021.03.2240

2021-01-01

European Journal of Gynaecological Oncology

Abstract:Objective: To describe the incidence, timing, and risk factors of venous thromboembolism (VTE) after surgery for gynecological cancer and to evaluate its effects of these events on survival. Methods: This was a retrospective analysis from January 2008 through December 2016 at a single center. Data were recorded on surgical procedures, patient demographic characteristics, type of malignancy and VTE, and mortality outcomes within 30 days after surgery. Significant variables related to VTE were evaluated using bivariate analysis, and Logistic regression models were used to assess risk factors for VTE. Results: The overall rate of postoperative VTE was 0.899% (36/4005) within 30 days after surgery. Of these rates, the rate in abdominal surgery was 1.56% (19/1220), and the rate in minimally invasive surgery (MIS) was 0.6% (17/2785). The median time from surgery to diagnosis was 8.5 days. In univariate analysis, VTE was statistically significantly associated with ovarian and fallopian cancer (P < 0.05), older age (P = 0.001), and blood transfusion (P < 0.001). A multivariate logistic regression model was used to adjust for variables with P < 0.2 in univariate analysis and found that except for age, the other variables continued to have a significant association with VTE. Conclusion: The second week after surgery might be high-risk period of VTE occuring, and ovarian and fallopian tube cancer, abdominal surgery, and blood transfusion might be significant risk factors for developing VTE.
Thromboprophylaxis in Cancer Patients Undergoing Surgery

Kay T Htun,Agnes Y Y Lee,Kay Htun,Agnes Lee

DOI: https://doi.org/10.1055/s-0037-1602666

2017-06-08

Seminars in Thrombosis and Hemostasis

Abstract:Abstract Venous thromboembolism (VTE) is a common, complex, and costly complication in cancer patients undergoing surgery. VTE risk varies with types of cancer surgery as well as patient-, cancer-, and treatment-associated factors. Current VTE preventive measures with pharmacological, mechanical, and combination of both are shown to be effective. Clinical questions remain and more research is needed, focusing on the role of thromboprophylaxis for minimally invasive surgery and major cancer surgery other than abdominal/pelvic surgery, as well as optimal duration of thromboprophylaxis in high-risk patients. Routine individual VTE risk assessment and better adherence to thromboprophylaxis guidelines may offer improved outcomes in cancer patients undergoing surgery. A summary of currently available evidence and consensus guidelines on the primary prevention of VTE in cancer patients undergoing various types of surgery is presented here.

peripheral vascular disease,hematology
Risk of Venous Thromboembolism by Cancer Type: A Network Meta-Analysis

Marissa B. Betts,Xuejun Liu,Daniela R. Junqueira,Kyle Fahrbach,Binod Neupane,Sarah Ronnebaum,Amol D. Dhamane

DOI: https://doi.org/10.1055/s-0044-1779672

2024-02-25

Seminars in Thrombosis and Hemostasis

Abstract:Patients with cancer have an increased risk of venous thromboembolism (VTE). Comparing tumor-specific VTE risk is complicated by factors such as surgery, disease stage, and chemotherapy. Network meta-analysis (NMA) using cancer types as network nodes enabled us to estimate VTE rates by leveraging comparisons across cancer types while adjusting for baseline VTE risk in individual studies. This study was conducted to estimate the risk of VTE by cancer type and factors influencing VTE risk. The Embase, MEDLINE, and Cochrane Library repositories were systematically searched to identify clinical trials and observational studies published from 2005 to 2022 that assessed the risk of primary cancer-related VTE among two or more distinct cancer types. Studies with similar cancer populations and study methods reporting VTE occurring within 1 year of diagnosis were included in the NMA. Relative VTE rates across cancer types were estimated with random-effects Bayesian NMAs. Absolute VTE rates were calculated from these estimates using the average VTE incidence in lung cancer (the most frequently reported type) as the "anchor." From 2,603 records reviewed, 30 studies were included in this NMA. The general network described 3,948,752 patients and 18 cancer types: 3.1% experienced VTE within 1 year of diagnosis, with cancer-specific rates ranging from 0.7 to 7.4%. Consistent with existing VTE risk prediction tools, pancreatic cancer was associated with higher-than-average VTE risk. Other cancer types with high VTE risk were brain and ovarian cancers. The relative rankings of VTE risk for certain cancers changed based on disease stage and/or receipt of chemotherapy or surgery. This study followed the methodology of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA).[29] The a priori –developed study protocol and statistical analysis plan are available from the corresponding author. The data that support the findings of this study are available from the corresponding author upon reasonable request. Concept and design: M.B., X.L., D.R.J., K.F., A.D.D. Data acquisition, analysis interpretation, and visualization: M.B., D.R.J., K.F., B.N., S.R. Statistical analysis: K.F., B.N. Drafting of the manuscript: M.B., D.R.J., S.R. Project administration: X.L., D.R.J. Critical revision of manuscript for important intellectual content: All authors. Article published online: 23 February 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

peripheral vascular disease,hematology
Risk of thrombosis and bleeding in gynecologic cancer surgery: systematic review and meta-analysis

Lauri I Lavikainen,Gordon H Guyatt,Anna L Luomaranta,Rufus Cartwright,Ilkka E J Kalliala,Rachel J Couban,Riikka L Aaltonen,Karoliina M Aro,Jovita L Cárdenas,P J Devereaux,Päivi J Galambosi,Fang Zhou Ge,Alex L E Halme,Jari Haukka,Matthew L Izett-Kay,Kirsi M Joronen,Päivi K Karjalainen,Nadina Khamani,Sanna M Oksjoki,Negar Pourjamal,ROTBIGGS Investigators,Tino Singh,Riikka M Tähtinen,Robin W M Vernooij,Kari A O Tikkinen,Kaisa Ahopelto,Yoshitaka Aoki,Ines Beilmann-Lehtonen,Marco H Blanker,Samantha Craigie,Jaana Elberkennou,Herney A Garcia-Perdomo,Huda A Gomaa,Peter Gross,Sakineh Hajebrahimi,Paul J Karanicolas,Tuomas P Kilpeläinen,Antti J Kivelä,Tapio Korhonen,Hanna Lampela,Yung Lee,Anne K Mattila,Borna Tadayon Najafabadi,Taina P Nykänen,Carolina Nystén,Sanjay Pandanaboyana,Chathura B B Ratnayake,Aleksi R Raudasoja,Ville J Sallinen,Philippe D Violette,Yingqi Xiao,Liang Yao

DOI: https://doi.org/10.1016/j.ajog.2023.10.006

Abstract:Objective: This study aimed to provide procedure-specific estimates of the risk of symptomatic venous thromboembolism and major bleeding in the absence of thromboprophylaxis, following gynecologic cancer surgery. Data sources: We conducted comprehensive searches on Embase, MEDLINE, Web of Science, and Google Scholar for observational studies. We also reviewed reference lists of eligible studies and review articles. We performed separate searches for randomized trials addressing effects of thromboprophylaxis and conducted a web-based survey on thromboprophylaxis practice. Study eligibility criteria: Observational studies enrolling ≥50 adult patients undergoing gynecologic cancer surgery procedures reporting absolute incidence for at least 1 of the following were included: symptomatic pulmonary embolism, symptomatic deep vein thrombosis, symptomatic venous thromboembolism, bleeding requiring reintervention (including reexploration and angioembolization), bleeding leading to transfusion, or postoperative hemoglobin <70 g/L. Methods: Two reviewers independently assessed eligibility, performed data extraction, and evaluated risk of bias of eligible articles. We adjusted the reported estimates for thromboprophylaxis and length of follow-up and used the median value from studies to determine cumulative incidence at 4 weeks postsurgery stratified by patient venous thromboembolism risk factors. The GRADE approach was applied to rate evidence certainty. Results: We included 188 studies (398,167 patients) reporting on 37 gynecologic cancer surgery procedures. The evidence certainty was generally low to very low. Median symptomatic venous thromboembolism risk (in the absence of prophylaxis) was <1% in 13 of 37 (35%) procedures, 1% to 2% in 11 of 37 (30%), and >2.0% in 13 of 37 (35%). The risks of venous thromboembolism varied from 0.1% in low venous thromboembolism risk patients undergoing cervical conization to 33.5% in high venous thromboembolism risk patients undergoing pelvic exenteration. Estimates of bleeding requiring reintervention varied from <0.1% to 1.3%. Median risks of bleeding requiring reintervention were <1% in 22 of 29 (76%) and 1% to 2% in 7 of 29 (24%) procedures. Conclusion: Venous thromboembolism reduction with thromboprophylaxis likely outweighs the increase in bleeding requiring reintervention in many gynecologic cancer procedures (eg, open surgery for ovarian cancer and pelvic exenteration). In some procedures (eg, laparoscopic total hysterectomy without lymphadenectomy), thromboembolism and bleeding risks are similar, and decisions depend on individual risk prediction and values and preferences regarding venous thromboembolism and bleeding.
Seek and ye shall find: The utility of perioperative VTE screening in high‐risk oncologic patients undergoing abdominopelvic surgery

Eric R. Pletcher,Allison Nguyen‐Thai,Tiffany Lim,Allan W. Silberman

DOI: https://doi.org/10.1002/jso.27609

2024-02-29

Journal of Surgical Oncology

Abstract:Background and Objective The aim of this study was to evaluate the prevalence and risk factors associated with perioperative venous thromboembolism (VTE) in patients undergoing major oncologic surgery using an epidural catheter (EC) for postoperative analgesia with mechanical prophylaxis and without chemoprophylaxis. Methods Six hundred and twenty‐six patients undergoing major oncologic surgery from 2009 to 2023 were evaluated. VTE was defined as deep vein thrombosis above the level of the knee. Lower extremity venous duplexes (LEVDs) were done preoperatively and postoperatively after the EC was removed. All patients received mechanical thromboprophylaxis, but not chemical prophylaxis, while the EC was in place. A generalized linear multivariable model was constructed to identify risk factors that predict pre and postoperative VTE. Results 29/626 patients (4.6%) were found to have preoperative VTE. 16/626 (2.6%) were found to have a postoperative VTE when their preoperative LEVD was negative. In comparison to patients without preoperative VTE, those with VTE were more likely to be male, anticoagulated, and have a history of coronary artery disease. Patients in the postoperative VTE group were older, male, anticoagulated, and had a history of VTE. On multivariable analysis, previous history of VTE was the risk factor most strongly associated with both pre and postoperative VTE. Conclusion Oncologic patients undergoing elective abdominopelvic surgery with epidural analgesia should be screened in the perioperative setting with LEVD to identify VTE and possibly prevent PE.

oncology,surgery
Venous thromboembolism after major gynecological cancer surgery: an analysis of cause and effect from the experience of a tertiary referral oncologic centre

M. D. Ray,N. Premanand,Saroj Rajan,Romey Rai,Premanand N.

DOI: https://doi.org/10.18203/2320-1770.ijrcog20233645

2023-11-28

Abstract:Background: Patients undergoing extensive gynecological oncologic surgeries are at greater risk for developing deep vein thrombosis and pulmonary embolism than other oncological procedures. The anatomical confinement of vessels, lymphatics, and other structures in the restrictive pelvic space is contributory. We aimed to establish the etiopathogenesis of venous thromboembolism (VTE) with our practical experience. Methods: We present our experience from a tertiary referral oncologic centre in north India in patients with ovarian cancer undergoing cytoreductive surgery (CRS) with or without HIPEC, with a focus on the incidence and etiopathogenesis of deep venous thromboembolism (DVT), including anatomical barriers, restricted movement during surgical dissection, risk stratification and preventive measures. Results: Of 250 patients who underwent cytoreductive surgery (CRS) for ovarian cancer, 124 additionally underwent hyperthermic intraperitoneal chemotherapy (HIPEC). 20 (8%) patients were diagnosed with DVT within 30 days of surgery, and 3 (1.2%) were detected after 30 days. It is the most common significant postoperative morbidity. Conclusions: DVT is the most common postoperative complication in patients undergoing CRS+HIPEC for carcinoma ovary. Anatomical confinement, closed dependant spaces and more significant surgical trauma to pelvic vessels and lymphatics may be the leading cause. Detailed knowledge of anatomy and careful surgical dissection may prevent the development of DVT.
The role of extended venous thromboembolism prophylaxis for major urological cancer operations

Rishi Naik,Indrajeet Mandal,Alexander Hampson,Tim Lane,Jim Adshead,Bhavan Prasad Rai,Nikhil Vasdev

DOI: https://doi.org/10.1111/bju.14906

Abstract:Objectives: Venous thromboembolism (VTE), consisting of both pulmonary embolism (PE) and deep vein thromboses (DVT), remains a well-recognised complication of major urological cancer surgery. Several international guidelines recommend extended thromboprophylaxis (ETP) with LMWH, whereby the period of delivery is extended to the post-discharge period, where the majority of VTE occurs. In this literature review we investigate whether ETP should be indicated for all patients undergoing major urological cancer surgery, as well procedure specific data that may influence a clinician's decision. Methods: We performed a search of six databases (PubMed, Cochrane, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), PsycINFO, and British Nursing Index (BNI)) from inception to June 2019, for studies looking at adult patients who received VTE prophylaxis after surgery for a major urological malignancy. Results: Eighteen studies were analysed. VTE risk is highest in open and robotic Radical Cystectomy (RC) (2.6-11.6%) and ETP demonstrates a significant reduction in risk of VTE, but not a significant difference in Pulmonary Embolism (PE) or mortality. Risk of VTE in open Radical Prostatectomy (RP) (0.8-15.7%) is comparable to RC, but robotic RP (0.2-0.9%), open partial/radical nephrectomy (1.0-4.4%) and robotic partial/radical nephrectomy (0.7-3.9%) were lower risk. It has not been shown that ETP reduces VTE risk specifically for RP or nephrectomy. Conclusion: The decision to use ETP is a fine balance between variables such as VTE incidence, bleeding risk and perioperative morbidity/mortality. This balance should be assessed for each specific procedure type. While ETP still remains of net benefit for open RP as well as open and robotic RC, the balance is closer for minimally invasive RP as well as radical and partial nephrectomy. Due to a lack of procedure specific evidence for the use of ETP, adherence with national guidelines remains poor. Therefore, we advocate further studies directly comparing ETP vs standard prophylaxis, for specific procedure types, in order to allow clinicians to make a more informed decision in future.
MPEG over ATM DBR service class for high quality transmission and effective bandwidth usage

N. Wakamiya,M. Murata,H. Miyahara

DOI: https://doi.org/10.1002/(SICI)1099-1131(199705/06)10:3%3C117::AID-DAC330%3E3.0.CO;2-G

1997-05-01

International Journal of Communication Systems

Abstract:The highly bursty nature of the moving picture experts group (MPEG) determines the bandwidth when it is applied to the asynchronous transfer mode (ATM) deterministic bit rate (DBR) service class. Furthermore, the MPEG source must declare peak cell rate (PCR), one of the traffic descriptors used in the call admission control (CAC) procedure, before actual transmission in ATM networks. However, the real-time encoding of the MPEG video introduces a difficulty in predicting a maximum picture size of the video, which is necessary to determine PCR. When an MPEG source can be equipped with the capability to adjust the encoding rate to the allocated bandwidth, the burstiness of the MPEG video can be lowered and the uncertainty in predicting PCR is avoided to some extent. In this case, a problem is apparently quality degradation caused by introducing such a rate adaptation mechanism, which is the main subject of this study. For the rate adaptation method, we consider a priority control method, a space reduction method, a time reduction method and a bandwidth renegotiation method. Quality of the video is evaluated and compared in terms of signal-to-noise ratio (SNR) as well as mean opinion score (MOS) because users' perception becomes an important measure of the quality of video transmissions. Through experimental results, it is shown that the space reduction method is useful for real-time transmission, whereas the time reduction method can be applicable if the users' application can tolerate the relatively large delay between source and destination. Furthermore, the applicability of the bandwidth renegotiation method is also validated. © 1997 by John Wiley & Sons, Ltd.
Adherence to Extended Venous Thromboembolism Prophylaxis and Outcomes After Complex Gastrointestinal Oncologic Surgery

Michail N. Mavros,Lauren A. Johnson,Mario Schootman,Sonia T. Orcutt,Cheng Peng,Bradley C. Martin

DOI: https://doi.org/10.1245/s10434-023-13677-z

IF: 4.339

2023-06-20

Annals of Surgical Oncology

Abstract:Abstract Background Clinical guidelines recommend extended venous thromboembolism (VTE) prophylaxis for cancer patients after major gastrointestinal (GI) operations. However, adherence to the guidelines has been low, and the clinical outcomes not well defined. Methods This study retrospectively analyzed a random 10 % sample of the 2009–2022 IQVIA LifeLink PharMetrics Plus database, an administrative claims database representative of the commercially insured population of the United States. The study selected cancer patients undergoing major pancreas, liver, gastric, or esophageal surgery. The primary outcomes were 90-day post-discharge VTE and bleeding. Results The study identified 2296 unique eligible operations. During the index hospitalization, 52 patients (2.2 %) experienced VTE, 74 patients (3.2 %) had postoperative bleeding, and 140 patients (6.1 %) had a hospital stay of at least 28 days. The remaining 2069 operations comprised 833 pancreatectomies, 664 hepatectomies, 295 gastrectomies, and 277 esophagectomies. The median age of the patients was 49 years, and 44 % were female. Extended VTE prophylaxis prescriptions were filled for 176 patients (10.4 % for pancreas, 8.1 % for liver, 5.8 % for gastric cancer, and 6.5 % for esophageal cancer), and the most used agent was enoxaparin (96 % of the patients). After discharge, VTE occurred for 5.2 % and bleeding for 5.2 % of the patients. The findings showed no association of extended VTE prophylaxis with post-discharge VTE (odds ratio [OR], 1.54; 95 % confidence interval [CI], 0.81–2.96) or bleeding (OR, 0.72, 95 % CI, 0.32–1.61). Conclusions The majority of the cancer patients undergoing complex GI surgery did not receive extended VTE prophylaxis according to the current guidelines, and their VTE rate was not higher than for the patients who received it.

oncology,surgery
The Epidemiology of Cancer-Associated Venous Thromboembolism: An Update

Anjlee Mahajan,Ann Brunson,Richard White,Ted Wun

DOI: https://doi.org/10.1055/s-0039-1688494

2019-04-30

Seminars in Thrombosis and Hemostasis

Abstract:Abstract The incidence of venous thromboembolism (VTE) is known to be higher in patients with malignancy as compared with the general population. It is important to understand and review the epidemiology of VTE in cancer patients because it has implications regarding treatment and prognosis. Multiple studies have shown that cancer patients who develop VTE are at higher risk for mortality. This article will focus on an update regarding the epidemiology of cancer-associated thrombosis (CT). The authors will describe factors associated with CT risk including cancer type and stage at the time of diagnosis, race and ethnicity, and cancer-directed therapy. In addition, recurrent thrombosis and the effect of thromboembolism on survival in cancer patients will also be addressed.

peripheral vascular disease,hematology
Risk factors for venous thromboembolism after vascular surgery and implications for chemoprophylaxis strategies

Zachary A Matthay,Colleen P Flanagan,Katherine Sanders,Eric J Smith,Elizabeth M Lancaster,Warren J Gasper,Lucy Z Kornblith,Jade S Hiramoto,Michael S Conte,James C Iannuzzi

DOI: https://doi.org/10.1016/j.jvsv.2021.10.001

Abstract:Objective: Venous thromboembolism (VTE) is an important cause of postoperative morbidity and mortality. However, the reported incidence after major vascular surgery has ranged from as low as 1% to >10%. Furthermore, little is known about optimal chemoprophylaxis regimens or rates of postdischarge VTE in this population. In the present study, we aimed to better characterize the rates of in-hospital and postdischarge VTE after major vascular surgery, the role of chemoprophylaxis timing, and the association of VTE with mortality. Methods: A single-center retrospective study of 1449 major vascular operations (2013-2020) was performed and included 189 endovascular abdominal aortic aneurysm repairs (13%), 169 thoracic endovascular aortic aneurysm repairs (12%), 318 open aortic operations (22%), 640 lower extremity bypasses (44%), and 133 femoral endarterectomies (9%). The baseline characteristics, anticoagulant and antiplatelet medications, and outcomes were abstracted from an electronic database with medical record auditing. Postoperative VTE (pulmonary embolism and deep vein thrombosis) within 90 days of surgery was classified by the location, symptoms, and treatment. A cut point analysis using Youden's index identified the most VTE discriminating timing of chemoprophylaxis (including therapeutic vs prophylactic anticoagulant and antiplatelet medications) and Caprini score. Multivariable logistic regression was used to test the association of VTE with chemoprophylaxis timing, Caprini score, and additional risk factors. Cox proportional hazard modeling was used to measure the association between VTE and mortality. Results: The overall VTE incidence was 3.4% (65% deep vein thrombosis; 25% pulmonary embolism; 10% both), and 37% had occurred after discharge. The rate of symptomatic VTE was 2.4%, which was lowest for endovascular abdominal aortic aneurysm repair (0.0%) and highest for open aortic surgery (4.1%; P = .02). Those who had developed VTE had had a longer length of stay, higher rates of end-stage renal disease and prior VTE, and higher Caprini scores (8 vs 5 points; P < .01 for all). Those who had developed VTE were also more likely to have received ≥2 U of blood postoperatively, required an unplanned return to the operating room, had delayed chemoprophylaxis, anticoagulation, and/or antiplatelet initiation of >4 days postoperatively, and had increased 90-day mortality (P < .01 for all). A Caprini score of ≥7 (29% of patients) was associated with postdischarge VTE (2.6% vs 0.7%; P = .01), and chemoprophylaxis, anticoagulation, and antiplatelet timing of >4 days was associated with an increased adjusted odds of VTE (odds ratio, 2.4; 95% confidence interval, 1.1-4.9). Although no fatal VTEs were identified, VTE was an independent predictor of 90-day mortality (adjusted hazard ratio, 2.7; 95% confidence interval, 1.3-5.9). Conclusions: These data have shown that patients undergoing major vascular surgery are particularly prone to the development of VTE, with frequent hypercoagulable comorbidities. The earlier initiation of chemoprophylaxis was associated with a reduced risk of VTE development. Furthermore, the postdischarge VTE rates might reach thresholds warranting postdischarge chemoprophylaxis, especially for patients with a Caprini score of ≥7.
Incidence and Risk Factors of Preoperative Venous Thromboembolism and Pulmonary Embolism in Patients with Ovarian Cancer.

Shanhui Liang,Wei Tang,Shuang Ye,Libing Xiang,Xiaohua Wu,Huijuan Yang

DOI: https://doi.org/10.1016/j.thromres.2020.02.019

IF: 10.407

2020-01-01

Thrombosis Research

Abstract:Introduction: To determine the incidence and predisposing factors of preoperative venous thromboembolism (VTE), especially pulmonary embolism (PE) in patients with ovarian cancer. Material and methods: This retrospective study included 387 patients with primary ovarian cancer, whose preoperative work up included both ultrasonography of lower extremity vein and spiral computed tomography pulmonary angiogram, from September 2013 to November 2016. SPSS 22 was used for statistical analyses. Results: The incidence of preoperative VTE and PE was 13.4% (52 patients), 9.3%(36 patients), respectively. Both the univariate and multivariate analyses revealed that D-dimer (DDI) level, age, and massive ascites were associated with preoperative VTE. Moreover, DDI level (odds ratio [OR] 3.133, 95% confidence interval [CI] 1.193-8.225, p=.02), massive ascites (OR 9.972, 95% CI 3.687-26.968, p <.001), and preoperative deep vein thrombosis (OR 5.977, 95% CI 2.073-17.228, p =.001) were independent predictors for preoperative PE. Additionally, the incidence of preoperative VTE and PE increased with increasing DDI levels (p <.001). DDI level < 1.5 mu g/ml has 100% negative predictive value and 100% sensitivity for diagnosis of preoperative VTE and PE; however, DDI> 5 mu g/ml, the incidence of preoperative VTE and PE were 18.4% and 14.2% respectively. Moreover, DDI value was significantly correlated with preoperative PE volume (r = 0.746, p <.001). Conclusion: Preoperative VTE and PE are common events in patients with ovarian cancer. DDI level is a useful parameter for diagnosing and evaluating preoperative VTE and PE.
Catheter and Non-Catheter-Related Venous Thromboembolism in Cancer Patients: Survival, Anticoagulation Efficacy, and Safety

Feng Liang,Min Chao,Kai-Yi Song,Hui-Qi Wang,Ling-Zhi Jiang,Xiang-Ming Ye

DOI: https://doi.org/10.1177/10760296241282771

Abstract:Purpose: To investigate the differences in survival after venous thromboembolism (VTE) and anticoagulation efficacy and safety between catheter (CRVTE) and non-catheter-related VTE (NCRVTE) in cancer patients. Methods: A retrospective research was conducted, and consecutive cancer (digestive, respiratory, genitourinary, blood and lymphatic, and the other cancers) patients with VTE were enrolled. The anticoagulation therapies included low-molecular-weight heparin (LMWH), warfarin, new type of direct oral anticoagulants (NDOACs), LMWH combined with warfarin, and LMWH combined with NDOACs. Data were collected from the electronic medical record database of our hospital and were analyzed accordingly by Kruskal-Wallis H Test, Chi-square test, Fisher's exact test, Logistic regressions, Kaplan-Meier analysis, and Cox regressions. Results: 263 patients were included, median age in years (interquartile range) was 64(56-71) and 60.5% were male. VTE recurrence rate was 16.7% in CRVTE group which was significantly lower than 34.8% in NCRVTE group (P = .032). Heart diseases were independently associated with VTE recurrence (P = .025). Kaplan-Meier survival estimates at 1, 2, and 3 years for CRVTE group were 62.5%, 60.0%, and 47.5%, respectively, compared with 47.9% (P = .130), 38.7% (P = .028), and 30.1% (P = .046), respectively, for NCRVTE group. Cox regression showed surgery (P = .003), anticoagulation therapy types (P = .009), VTE types (P = .006) and cancer types (P = .039) were independent prognostic factors for 3-year survival after VTE. Nonmajor and major bleeding were not significantly different (P = .417). Anticoagulation therapy types were independently associated with the bleeding events (P = .030). Conclusions: Cancer patients with CRVTE potentially have a better anticoagulation efficacy and survival compared to NCRVTE, and the anticoagulation safety seems no significant difference.
Effectiveness and safety of expanded perioperative thromboprophylaxis in complex gynecologic surgery

Bradley R. Corr,Andrea M. Winter,Mary D. Sammel,Christina S. Chu,Brian F. Gage,Andrea R. Hagemann

DOI: https://doi.org/10.1016/j.ygyno.2015.07.017

IF: 5.304

2015-09-01

Gynecologic Oncology

Abstract:OBJECTIVE: To determine the effectiveness and safety of an expanded perioperative venous thromboembolism (VTE) prophylaxis strategy in women undergoing complex gynecologic surgery.METHODS: We performed a cohort study of 527 patients undergoing major surgery at a single institution over a thirty-month interval during which the gynecologic oncology service implemented an expanded approach to VTE prophylaxis. We compared rates of VTE pre- and post-intervention as well as bleeding and infectious complications.RESULTS: Prior to the intervention, there were 23 VTE events in 345 patients (rate of 6.67%): 8 deep vein thromboses (DVTs) and 15 pulmonary emboli (PEs). Post-intervention, there were 5 VTE events in 182 patients (2.7%): 3 DVTs and 2 PEs (RR=0.4, p=0.056). Time-to-event analysis showed a significantly higher incidence of VTE events in the pre-intervention time frame compared to the post-intervention period (p=0.049). There were no significant differences in bleeding or infection complications between groups.CONCLUSIONS: Implementation of a perioperative VTE prophylaxis protocol was safe, feasible and resulted in a clinically significant reduction in symptomatic VTE. Preoperative single-dose unfractionated heparin for all patients, combined with two weeks of thromboprophylaxis in gynecologic cancer patients, may decrease VTE events without increasing bleeding or infection.

oncology,obstetrics & gynecology
[What is the normal value?].

M. Kitamura

DOI: https://doi.org/10.11389/JJRS1963.17.597

1979-10-25

Abstract:

Analysis of intercellular calcium signaling using microfluidic adjustable laminar flow for localized chemical stimulation.

Comparison of Artificial Neural Network and Regression Models in the Prediction of Urban Stormwater Quality

Predictors of Venous Thromboembolism after Lung Cancer Resection

Incidence and timing of venous thromboembolism after surgery for gynecological cancer

Venous Thromboembolism Chemoprophylaxis Adherence Rates After Major Cancer Surgery

Postoperative Venous Thromboembolism in Colon and Rectal Cancer: Do Tumor Location and Operation Matter?

Incidence and Predictors of Venous Thromboembolism after Surgery for Gynecologic Cancer

Thromboprophylaxis in Cancer Patients Undergoing Surgery

Risk of Venous Thromboembolism by Cancer Type: A Network Meta-Analysis

Risk of thrombosis and bleeding in gynecologic cancer surgery: systematic review and meta-analysis

Seek and ye shall find: The utility of perioperative VTE screening in high‐risk oncologic patients undergoing abdominopelvic surgery

Venous thromboembolism after major gynecological cancer surgery: an analysis of cause and effect from the experience of a tertiary referral oncologic centre

The role of extended venous thromboembolism prophylaxis for major urological cancer operations

MPEG over ATM DBR service class for high quality transmission and effective bandwidth usage

Adherence to Extended Venous Thromboembolism Prophylaxis and Outcomes After Complex Gastrointestinal Oncologic Surgery

The Epidemiology of Cancer-Associated Venous Thromboembolism: An Update

Risk factors for venous thromboembolism after vascular surgery and implications for chemoprophylaxis strategies

Incidence and Risk Factors of Preoperative Venous Thromboembolism and Pulmonary Embolism in Patients with Ovarian Cancer.

Catheter and Non-Catheter-Related Venous Thromboembolism in Cancer Patients: Survival, Anticoagulation Efficacy, and Safety

Effectiveness and safety of expanded perioperative thromboprophylaxis in complex gynecologic surgery

[What is the normal value?].